WilmerHale Represents Ocular Therapeutix™ in Public Offering of Common Stock

WilmerHale Represents Ocular Therapeutix™ in Public Offering of Common Stock

News

On January 29, 2018, Ocular Therapeutix™, Inc. (NASDAQ: OCUL) announced the closing of its underwritten public offering of 7,475,000 shares of its common stock at a public offering price of $5.00 per share. The shares of common stock issued and sold in the offering at the closing include 975,000 shares issued upon the exercise in full by the underwriter of its option to purchase additional shares at the public offering price, less underwriting discounts and commissions. The offering was made pursuant to a shelf registration statement that was previously filed with and declared effective by the Securities and Exchange Commission. All of the shares in the offering were sold by Ocular.

WilmerHale's Brian Johnson advised Ocular in this transaction with a team that included Ryan Mitteness, Michael Raine, Avery Reaves, Jasmine Haddad and Heidi Treiber.

Ocular's press release is available at www.ocutx.com.